Category: Uncategorized
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024
CARMEL, Ind., August 7, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that the U.S. Food and Drug administration (FDA) has cleared the Investigational New Drug (IND) application for MBX 1416, the company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for the treatment of post-bariatric hypoglycemia (PBH).
“IND clearance for MBX 1416 marks a significant milestone for our team, as we advance our second innovative PEP candidate into the clinic,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “As a potential first-in-class therapy for PBH, we believe MBX 1416 may prevent severe hypoglycemia and its associated symptoms and meaningfully improve patients’ lives. We look forward to initiating the Phase 1 trial later this quarter.”
MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for PBH. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypoglycemia in individuals with PBH so they can lead healthier and more independent lives. MBX expects to initiate enrollment in a Phase 1 trial in the third quarter of 2023 and anticipates reporting topline results in the second half of 2024.
About Post-Bariatric Hypoglycemia
Post-bariatric hypoglycemia (PBH) is a rare disease and a serious complication of bariatric surgery. PBH is characterized by repeated episodes of symptomatic hypoglycemia, triggered by excessive insulin levels following a meal, and generally presents as early as six months after Roux-en-Y gastric bypass (RYGB). Hypoglycemic episodes can occur multiple times per day and can periodically manifest with severe symptoms such as dizziness, confusion, loss of consciousness or seizure due to glucose deficiency in the brain. The unpredictability of hypoglycemic episodes and their associated risks may meaningfully hinder daily activities. As a result, the patient burden can be substantial, and many individuals cannot drive, work or live alone. To date, there are no approved pharmacotherapies to treat PBH. As the use of surgery to address metabolic conditions continues to rise, the incidence of PBH is expected to increase, reinforcing the need for safe and effective therapies.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX’s pipeline includes its lead product candidate MBX 2109, currently in Phase 1 development for the treatment of hypoparathyroidism (HP), and MBX 1416, entering Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH). The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Contact:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Contact:
Irina Koffler
LifeSci Advisors
[email protected]
917-734-7387
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
CARMEL, Ind., July 10, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer (CSO). Dr. Prestrelski is a seasoned biopharmaceutical executive with over 30 years of scientific and operational expertise who has led successful endocrine and metabolism product development programs from discovery through regulatory approval.
“I’m pleased to welcome Steve to the MBX leadership team as our CSO,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “He has an impressive track record in building and operating impactful scientific organizations, and I am confident he will strengthen our entire research team and favorably position the company for future growth. We look forward to Steve’s contributions during this pivotal time for our peptide development programs, which aim to address the needs of underserved patients with endocrine disorders.”
“I am delighted to join MBX Biosciences during this exciting growth phase for the company,” said Steven Prestrelski, Ph.D., M.B.A., Chief Scientific Officer of MBX Biosciences. “Its impressive Precision Endocrine Peptide platform has the potential to generate enhanced therapeutics for several important indications, including Hypoparathyroidism (HP) and Post-Bariatric Hypoglycemia (PBH). I look forward to working with the MBX team to advance its scientific programs and develop innovative peptide therapeutics for patients with unmet medical needs.”
In parallel with Dr. Prestrelski joining MBX, Richard DiMarchi, Ph.D., will transition his role to focus on designing transformative molecules and expanding the MBX platform technology through sponsored research at Indiana University. Dr. DiMarchi will continue to support MBX as a consulting scientific advisor, principal investigator and member of the Board of Directors.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Irina Koffler
LifeSci Advisors
917-734-7387
MBX Biosciences to Participate in May Investor Conferences
CARMEL, Ind., May 8, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced management will participate in the following investor conferences.
JMP Securities Life Sciences Conference:
| Date: | Monday, May 15th, 2023 |
| Format: | Corporate Presentation by Kent Hawryluk, President and CEO, and 1×1 Investor Meetings |
| Time: | 1:00 PM ET |
| Location: | New York, NY |
Piper Sandler Spring Biopharma Symposium:
| Date: | Wednesday, May 17th, 2023 |
| Format: | 1×1 Investor Meetings |
| Location: | Boston, MA |
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. The Company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Irina Koffler
LifeSci Advisors
917-734-7387
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
CARMEL, Ind., April 10, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced its participation at the virtual Needham 22nd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Monday, April 17, 2023 at 3:00 p.m. ET and management will be available for one-on-one meetings with institutional investors throughout the day.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Irina Koffler
LifeSci Advisors
917-734-7387
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
CARMEL, Ind., January 24, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced its participation at the virtual SVB Securities Global Biopharma Conference – Private Company Track. The conference will take place January 31 – February 2, 2023 and management will be available for one-on-one meetings with institutional investors during that time.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Robert Uhl
ICR Westwicke
619-228-5886
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
CARMEL, Ind., January 4, 2023 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced its participation at the 41st Annual J.P. Morgan Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Thursday, January 12, 2023 at 11:00 AM PST. The conference will take place on January 9 – 12, 2023 in San Francisco and management will be hosting 1×1 institutional investor meetings during that time.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, NEA, OrbiMed, Wellington Management, RA Capital Management and Norwest Venture Partners. MBX is based in Carmel, Indiana. To learn more, visit the www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Robert Uhl
ICR Westwicke
619-228-5886
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Financing led by Wellington Management with participation from other leading healthcare funds
CARMEL, Ind., November 14, 2022 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the closing of a $115 million Series B financing. The Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board.
“MBX has grown tremendously as a company since closing our Series A two years ago, including bringing our lead program MBX 2109 into the clinic, achieving proof of mechanism and now starting the multiple ascending dose portion of our Phase 1 trial,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “With the support of these leading healthcare investors, we look forward to further advancing our Precision Endocrine Peptides as part of our goal to improve outcomes and quality of life for patients with endocrine disorders.”
Proceeds of the financing will support MBX into early 2025 as it develops transformative therapeutics known as Precision Endocrine Peptides (PEPs™) designed to overcome limitations of traditional peptide therapeutics. This includes continued clinical advancement of its lead product candidate, MBX 2109, which is in development for the treatment of hypoparathyroidism and currently in a Phase 1 clinical trial. In addition, proceeds will support the company’s preclinical pipeline, led by MBX 1416, and discovery programs in endocrine diseases.
“We are encouraged by the progress that MBX has made to date, including advancing its PEP therapeutic candidates and building a strong team to lead the organization into the future,” said Nilesh Kumar, Ph.D., Co-Head, Biotech Private Investment at Wellington Management. “We believe the company is well positioned to bring significant benefit to patients with endocrine disorders, and we are pleased to join a great investor syndicate in supporting the company.”
About Hypoparathyroidism
Hypoparathyroidism (HP) is a rare endocrine disorder caused by a deficiency of parathyroid hormone that results in decreased calcium and increased phosphorus levels in the blood. HP affects approximately 200,000 individuals worldwide, most of whom develop the condition following damage to or removal of the parathyroid glands during thyroid surgery. It is a complicated disorder associated with a wide range of symptoms including paresthesias, muscle cramps, seizures, an impaired quality of life, and an increased risk of comorbidities including kidney stones and impaired renal function. The goal of treatment is to maintain blood calcium levels in the low-normal range while preventing symptoms of hypocalcemia. Current standard of care consists of high doses of calcium supplements and active vitamin D, which may contribute to the risk of renal disease and does not address the underlying pathophysiology which is to restore the missing hormone.
About MBX 2109
MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for the treatment of hypoparathyroidism. It was designed with the company’s novel, proprietary Precision Endocrine Peptide™ (PEP™) platform to provide sustained PTH activity with a convenient once-weekly dosing regimen. In July 2022, MBX 2109 received Orphan Drug designation from the U.S. Food and Drug Administration. MBX aims to simplify an individual’s disease management, while relieving both the symptoms of the disorder and long-term complications.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, NEA, OrbiMed, Wellington Management, RA Capital Management and Norwest Venture Partners. MBX is based in Carmel, Indiana. To learn more, visit the www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Robert Uhl
ICR Westwicke
619-228-5886
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
MBX 2109 is in clinical development for treatment of hypoparathyroidism
CARMEL, Ind., Oct. 05, 2022 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that it has initiated the multiple ascending dose portion of its ongoing Phase 1 clinical trial of MBX 2109. MBX 2109, the company’s lead investigational drug, is a long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism.
“This is an exciting achievement for MBX as we continue to advance our first clinical program,” said Kent Hawryluk, president and chief executive officer of MBX Biosciences. “We believe MBX 2109 has the potential to address a substantial need in hypoparathyroidism, and this trial brings us a step closer to evaluating it in patients.”
The randomized, double blind, placebo-controlled Phase 1 trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of MBX 2109 in healthy adult subjects. The single ascending dose portion of the trial, which began at the end of 2021, was completed successfully. MBX 2109 was observed to be safe and well tolerated, as compared to placebo. For the multiple ascending dose phase of the trial, subjects are to receive either MBX 2109 or placebo once weekly subcutaneously for four weeks. The primary outcome measures will evaluate safety and tolerability. Secondary outcome measures will evaluate pharmacokinetics and pharmacodynamics. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05158335.
About Hypoparathyroidism
Hypoparathyroidism (HP) is a rare endocrine disorder caused by a deficiency of parathyroid hormone that results in decreased calcium and increased phosphorus levels in the blood. HP affects approximately 200,000 individuals worldwide, most of whom develop the condition following damage to or removal of the parathyroid glands during thyroid surgery. It is a complicated disorder associated with a wide range of symptoms including paresthesias, muscle cramps, seizures, an impaired quality of life, and an increased risk of comorbidities including kidney stones and impaired renal function. The goal of treatment is to maintain blood calcium levels in the low-normal range while preventing symptoms of hypocalcemia. Current standard of care consists of high doses of calcium supplements and active vitamin D, which may contribute to the risk of renal disease and does not address the underlying pathophysiology which is to restore the missing hormone.
About MBX 2109
MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy. It was designed with the company’s novel, proprietary Precision Endocrine Peptide™ (PEP™) platform to provide sustained PTH activity with a convenient once-weekly dosing regimen. MBX aims to simplify an individual’s disease management, while relieving both the symptoms of the disorder and long-term complications.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides™ (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed. For more information, please visit the MBX website and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Evoke Canale
[email protected]
619-849-5388
Investor Inquiries:
Robert Uhl
ICR Westwicke
[email protected]
619-228-5886
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
CARMEL, Ind., July 26, 2022 — MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to its lead therapeutic product candidate, MBX 2109, for the treatment of hypoparathyroidism.
“This is an exciting achievement for MBX and underscores the significant need to expand treatment options for hypoparathyroidism,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “We believe MBX 2109, currently in a Phase 1 clinical trial, has the potential to overcome limitations of the current standard of care with fewer administrations necessary due to its long-acting profile. Our goal is to improve the outcomes and quality of life for patients with this chronic condition.”
Orphan drug designation is designed to support the development of medicines addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.
MBX 2019 is an investigational long-acting parathyroid hormone (PTH) prodrug. It is currently undergoing evaluation in a Phase 1 randomized, double blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of MBX 2109 in healthy adult subjects. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05158335.
About Hypoparathyroidism
Hypoparathyroidism (HP) is a rare endocrine disorder caused by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and increased phosphorus levels in the blood. There are approximately 200,000 individuals worldwide with HP. The clinical manifestations are broad affecting a large number of organ systems, especially the kidney and bone which are major target organs for PTH. The persistence of symptoms and development of complications often diminish a person’s quality of life. In contrast to most hormone deficiencies for which hormone replacement therapy is the mainstay of therapy, HP has conventionally been treated with calcium supplements and active vitamin D. This approach can maintain the serum calcium level but may require high doses thereby contributing to the risk of long-term kidney complications.
About MBX 2109
MBX 2109 is an investigational long-acting parathyroid hormone (PTH) prodrug in development as a PTH replacement therapy. It was designed with the company’s novel, proprietary prodrug chemistry platform to provide sustained PTH activity with a convenient once-weekly dosing regimen to simplify an individual’s disease management, while relieving both the symptoms of the disorder and long-term complications.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed. For more information, please visit the MBX website and follow us on LinkedIn and Twitter.
Media Inquiries:
Ian Stone
Canale Communications
[email protected]
619-849-5388
Investor Inquiries:
Robert Uhl
ICR Westwicke
[email protected]
619-228-5886
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
CARMEL, Ind., April 11, 2022 – MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine disorders, today announced the appointment of Richard B. Bartram, as Chief Financial Officer. Mr. Bartram is a proven financial executive with an extensive understanding of the capital markets and a wide variety of experience in private transactions, initial public offerings, follow-on equity offerings, debt offerings, and other financial transactions.
“I am delighted to welcome Rick to the MBX leadership team as our CFO and look forward to benefitting from his financial acumen as we strive to advance our innovative pipeline of programs aimed at the development of new medicines for patients with endocrine disorders,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “He has the experience, and the right financial and business skill set to be a driving force in our future growth.”
Most recently, Mr. Bartram served as Chief Financial Officer at Esperion Therapeutics Inc., a publicly traded pharmaceutical company focused on the development and commercialization of therapies for patients with elevated LDL cholesterol. During his time at Esperion, he led the company’s successful efforts to raise more than $1.2 billion in capital, supporting the approval and commercialization of both NEXLETOL® and NEXLIZET®. In addition, he provided key contributions to several successful business development licensing transactions. Prior to his tenure at Esperion, Mr. Bartram served as an assurance manager with PricewaterhouseCoopers LLP from 2005 to 2013. He earned his undergraduate and graduate degrees in Accounting from Michigan State University, and is a Certified Public Accountant.
“I am thrilled to join MBX Biosciences at such an exciting time of opportunity for the company,” said Mr. Bartram. “I look forward to helping the company reach its strategic and financial objectives as it develops innovative medicines for the patients who need them.”
About MBX Biosciences
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed. For more information, please visit www.mbxbio.com or follow-us on LinkedIn.
Media Inquiries:
Ian Stone
Canale Communications
[email protected]
619-849-5388
Investor Inquiries:
Robert Uhl
ICR Westwicke
[email protected]
619.228.5886